[Comparison of immunosuppressive effects between human placental MSCs derived from fetal and maternal origins on the rejection of allogenic skin grafts in mice].
OBJECTIVE
To compare the immunosuppressive effects of maternal and fetal placental mesenchymal stem cells (mPMSCs and fPMSCs, respectively) on the rejection of allogenic skin transplants in mice, and further to investigate the mechanism underlying this suppression.


METHODS
The mPMSCs and fPMSCs were isolated from human term placentas. The expressions of cell surface markers were detected by flow cytometry. Cell proliferation capacity was characterized by MTT colorimetric assay. CD200 protein expressed on fPMSCs was neutralized with streaming monoclonal antibodies, and mPMSCs were infected with adenovirus expression vector carrying CD200 cDNA. For skin transplantation, 60 C57BL/6 mice were randomly divided into 6 groups as skin transplant recipients, and ICR mice served as skin donors. After establishment of the allogenic skin transplants, recipient mice of the 6 groups were intravenous injected respectively with PBS, mPMSCs, fPMSCs, fPMSCs combined with anti-CD200 antibodies, mPMSCs with CD200 expressing vectors, and mPMSCs with empty vectors. The conditions and survival time of the skin grafts were inspected daily, and the expressions of interleukin 17 (IL-17), interferon γ (IFN-γ), tumor necrosis factor α (TNF-α) and interleukin 12 (IL-12) in blood and spleen were measured at the end of the study by ELISA and reverse transcription PCR.


RESULTS
The majority (>70%) of fPMSCs were detected CD200 positive, while only a minor fraction (about 2%) of CD-200 positive cells were seen in mPMSCs. In the allogenic skin graft mice, the graft survival time in both mPMSCs- and fPMSCs-treated groups were significantly longer than that in PBS group [(5.6±1.17) days], while the fPMSCs group [(10.6±1.43) days] was more dominant than mPMSCs group [(7.7±1.42) days]. Neutralizing anti-CD200 antibody reduced the graft survival [(8.2±1.14) days] of the fPMSCs group to the level of that in mPMSCs group, while enforced expression of CD200 increased the graft survival [(10.7±1.34) days] of the mPMSCs group to the level of the fPMSCs group. The empty vector-transfected mPMSCs showed a similar effect on graft survival [(7.8±1.32) days] as that in mPMSCs group, longer than PBS group but shorter than fPMSCs and mPMSCs combined with CD200 groups. Comparing with PBS group, the expressions of IL-17, IFN-γ and TNF-α were significantly reduced in mPMSCs and fPMSCs groups. The reduction of these cytokine expressions in the fPMSCs group was neutralized when anti-CD200 antibody was applied, while this reduction in the mPMSCs-treated mice was further enhanced when the mPMSCs were enforced to express CD200.


CONCLUSIONS
The immunosuppressive effect of fPMSCs on the rejection of allogenic skin transplantation was higher than that of mPMSCs, and this difference was partially contributed by CD200 signaling pathway. The mechanism of this suppression may mediate the inhibition of IL-17, IFN-γ, TNF-α and IL-12 expressions. The fPMSCs may be a suitable choice for immunosuppression on skin transplantation.
Department of Medical Laboratory, Ningxia Medical University, Yinchuan 750004, China.
Guiliang
G
Hao
Institute of Human Stem Cell, General Hospital, Ningxia Medical University, Yinchuan 750004, China.
Libin
L
Wang
Institute of Human Stem Cell, General Hospital, Ningxia Medical University, Yinchuan 750004, China.
Dongmei
D
Chen
Institute of Human Stem Cell, General Hospital, Ningxia Medical University, Yinchuan 750004, China.
Xueyun
X
Liang
BenQ International Medical Center, Nanjing 210000, China.
Qiong
Q
Wang
Institute of Human Stem Cell, General Hospital, Ningxia Medical University, Yinchuan 750004, China.
Yongzhao
Y
Zhu
Institute of Human Stem Cell, General Hospital, Ningxia Medical University, Yinchuan 750004, China.
Xiaona
X
Ma
Institute of Human Stem Cell, General Hospital, Ningxia Medical University, Yinchuan 750004, China.
Xiaoming
X
Liu
Institute of Human Stem Cell, General Hospital, Ningxia Medical University, Yinchuan 750004, China.
Yukui
Y
Li
D000818:Animals; D049109:Cell Proliferation; D005260:Female; D005333:Fetus / Q000166:cytology*; D005434:Flow Cytometry; D006084:Graft Rejection / Q000097:blood / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007371:Interferon-gamma / Q000097:blood / Q000235:genetics; D020381:Interleukin-17 / Q000097:blood / Q000235:genetics; D059630:Mesenchymal Stem Cells / Q000166:cytology / Q000276:immunology*; D051379:Mice; D009035:Mothers; D010920:Placenta / Q000166:cytology*; D011247:Pregnancy; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D016038:Skin Transplantation / Q000009:adverse effects*; D013154:Spleen / Q000276:immunology / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000097:blood / Q000235:genetics
D020381:Interleukin-17; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma